1	Lower Cancer Incidence Three Years After COVID-19 Infection in a Large Veteran Population
2	
3	Jerry Bradley, MD <sup>1</sup> , Fei Tang PhD <sup>2</sup> , Natasha Resendes MD <sup>1,2</sup> , Dominique Tosi MD <sup>1,2</sup> , Iriana
4	Hammel MD <sup>1,2*</sup>
5	
6	
7	<sup>1</sup> Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA
8	<sup>2</sup> Miami Veterans Administration (VA)Healthcare System Geriatric Research, Education, and
9	Clinical Center (GRECC), Miami, Florida, USA
10	
11	
12	
13	
14	*Corresponding author
15	Email: iriana.hammel@va.gov
16	
17	
18	

### 19 Abstract

Background: The role of COVID-19 infection in cancer incidence risk is not known. COVID-19
infection could lead to increased cancer risk, as seen with other viruses, or it could lead to
decreased risk due to the activation of the immune response during acute infection. This study
aimed to determine the association between cancer incidence in US Veterans after COVID-19
infection.

25 Methods: We conducted a retrospective cohort study of US Veterans comparing those who

tested positive for COVID-19 during the first wave of COVID-19 between March 15, 2020, and

27 Nov 30, 2020, to those who tested negative. We used data from the COVID-19 Shared Data

28 Resource and used Cox proportional hazard regression models to determine the hazard ratio of a

29 new cancer diagnosis within a three-year follow-up period for the COVID-19 positive patients

30 compared to those who were negative. Covariates included age, race, ethnicity, sex, BMI,

31 smoking, being an active patient in the VHA system in the past 12 months of the COVID-19 test,

32 and other factors.

33 **Results**: 516156 patients were included in this study, with 88590 (17.2%) COVID-19 positive,

34 427566 (82.8%) COVID-19 negative. The ages of the COVID-19 positive and negative patients

35 were 57.8±16.4 and 59.4±15.8, respectively. For those who survived for at least 30 days after

36 COVID-19 testing, COVID-19 infection was associated with a 32% reduction in the hazard of

37 cancer. The reduction of the hazard was similar across sexes and races, except in Asians. Above

38 45 years of age, the hazard of cancer incidence further decreases with advancing age.

- 39 Conclusions: Patients who were diagnosed with COVID-19 in the first wave of the pandemic
- 40 had a decreased risk of cancer incidence in a 3-year follow-up across gender and race. Further
- 41 multicenter prospective cohort studies are needed to evaluate the mechanism of this interaction.

# 42 Introduction

60

43	The COVID-19 pandemic has introduced a new viral factor with relatively unknown
44	effects on cancer development. Approximately 10% of cancers worldwide are virus-induced,
45	with Epstein-Barr virus (EBV), Hepatitis C virus (HCV), and human papillomavirus (HPV)
46	being examples of known viral oncogenic drivers (1). The mechanism by which viruses lead to
47	cancer development might be driven by the dysregulation of signaling pathways and alterations
48	in host DNA and RNA processes (2-4). It is unknown if, during the acute infection state of
49	COVID-19, dysregulation in immune signaling (5, 6), DNA damage with activation of pro-
50	inflammatory processes (7), or other mechanisms might increase the risk of cancer development.
51	Early in the pandemic, researchers were aware that COVID-19 induced morphological
52	and inflammatory changes in peripheral blood monocytes (8). However, the significance of these
53	changes has been debated. A recent analysis by Dr. Bharat et al. found that COVID-19 could
54	induce non-classical monocytes to act with anticancer properties (9). Specifically, they found
55	that COVID-19 single-stranded RNA (ssRNA), unlike influenza ssRNA, could increase the
56	population of this monocyte line. (9). The implication of these changes as a function of
57	monocyte exposure to COVID-19 ssRNA raises the question of whether contracting COVID-19
58	may affect cancer development in the short term.
59	Our team set out to compare the incidence of cancer in patients with COVID-19 to those

61 patients who were exposed to COVID-19 as compared to non-exposed patients.

4

without. We hypothesized that patients would have a reduced risk of cancer across the board in

## 62 Methods

### 63 Study Design, Data Sources, and Study Population

64 We conducted a retrospective cohort study to assess the association between COVID-19

65 infection and new cancer diagnoses in Veterans who were free of cancer at baseline. We

66 included Veterans who tested positive for the first time for SARS-CoV-2 (polymerase chain

67 reaction or antigen test) in VA medical centers or clinics between March 15, 2020, and

68 November 30, 2020 (Alpha/Beta waves). The control group included Veterans who had a

69 negative test result in this time frame and did not report positive test results in the next three

70 years. We excluded patients who had any cancer diagnosis at baseline and those who died within

71 30 days after SARS-CoV-2 infection. We used nationwide data from the VHA medical centers

72 from the VA COVID-19 Shared Data Resource. The Miami Veterans Affairs Healthcare System

73 Institutional Review Board approved this study. The IRB granted a waiver for informed consent.

74 The data was fully anonymized according to VHA standards prior to analysis. The data was

75 accessed on 01/10/2024 to 17/12/2024.

#### 76 Study Outcome

The primary outcome was any cancer diagnosis after COVID-19 testing (positive or negative) asdocumented by ICD-10 codes.

### 79 Covariates

80 Age, race, ethnicity, sex, BMI, smoking, kidney disease, COPD, diabetes, hypertension,

81 hyperlipidemia, obesity, chronic lung disease, PTSD, alcohol dependence, drug dependence,

82 being an active patient in the past 12 months, exposure to toxic substances, other viral infections

such as a history of exposure to Hepatitis B, Hepatitis C, cytomegalovirus, mononucleosis, HIV
among others, and immunodeficiency conditions secondary to prior history transplant or
conditions related to immune response.

### 86 Statistical Analysis

87 Continuous variables are presented as mean  $\pm$  standard deviation, median with interguartile 88 range, and categorical variables as frequencies and percentages. When information on race, 89 ethnicity and smoking status was not available, we reported the data as "Unknown." The Cox 90 proportional hazard model was used to evaluate the association between COVID-19 and cancer 91 diagnosis, adjusting for the covariates listed above. The proportional hazards assumption was 92 assessed and verified by testing the correlation between the Schoenfeld residuals and survival 93 time. Time-to-event analyses began 30 days after the date of infection, and patients were 94 censored on the date of death or at the end of the years of follow-up. The association was also 95 assessed in patients of different age groups, sexes, and races. Statistical analysis was performed 96 using R (R project for statistical computing, version 4.0.5).

# 97 Results

### 98 Baseline Characteristics

99 A total of 516,156 Veterans with SARS-CoV-2 testing in 2020 were included in this

100 retrospective cohort study, with 346,084 (67.1%) white, 112,476 (21.8%) black, 44,392 (8.6%)

101 Hispanic, 45,5388 (88.2%) males. A total of 88,590 (17.2%) patients tested positive for SARS-

102 CoV-2. The baseline characteristics of the study cohort are summarized in Table 1. The mean

age of the entire cohort was 59.1±16.0 years (median 62 years), with COVID-19 positive and

### 104 negative patients having similar ages (57.8±16.4 vs 59.4±15.8). The COVID-19 positive and

	Total n = 516156 (100%)	COVID-19 Negative n = 427566 (82.8%)	COVID-19 Positive n = 88590 (17.2%)
Age, mean (years) ±SD	59.1±16.0 (62; 48-71)	59.4±15.8 (62; 49-71)	57.8±16.4 (59; 45-71)
(median; IQR)			
Age Groups, n (%)			
19-64	220523 (42.7%)	185873 (43.5%)	34650 (39.1%)
≥65	295633 (57.3%)	241693 (56.5%)	53940 (60.9%)
Male sex, n (%)	455388 (88.2%)	376833 (88.1%)	78555 (88.7%)
Race, n (%)			
White	346084 (67.1%)	288910 (67.6%)	57174 (64.5%)
Black	112476 (21.8%)	91545 (21.4%)	20931 (23.6%)
Asian	6256 (1.2%)	5397 (1.3%)	859 (1.0%)
American Indian or	4378 (0.8%)	3496 (0.8%)	882 (1.0%)
Alaska Natives			
Native Hawaiian or	4783 (0.9%)	3919 (0.9%)	864 (1.0%)
Other Pacific Islander			
Unknown	42179 (8.2%)	34299 (8.0%)	7880 (8.9%)
Ethnicity, n (%)			
Hispanic	44392 (8.6%)	34365 (8.0%)	10027 (11.3%)
Not Hispanic	457677 (85.7%)	381616 (89.3%)	76061 (85.9%)
Unknown	14087 (2.7%)	11585 (2.7%)	2502 (2.8%)
Smoking, n (%)			
Current	109559 (21.2%)	98650 (23.1%)	10909 (12.3%)
Former Smoker	192443 (37.3%)	157933 (36.9%)	34510 (39.0%)
Never	169205 (32.8%)	134629 (31.5%)	34576 (39.0%)
Unknown	44949 (8.7%)	36354 (8.5%)	8595 (9.7%)
Comorbidity, n (%)			
Kidney Disease	101248 (19.6%)	84599 (19.8%)	16649 (18.8%)
COPD	84592 (16.4%)	73056 (17.1%)	11536 (13.0%)
Diabetes	153007 (29.6%)	125141 (29.3%)	27866 (31.5%)
Hypertension	296271 (57.4%)	246537 (54.5%)	49734 (54.8%)
Chronic Lung Disease	160078 (31.0%)	135996 (31.8%)	24082 (27.2%)
Overweight	35361 (6.9%)	27676 (8.7%)	7685 (6.5%)
Toxic exposure	3911 (0.8%)	3321 (0.8%)	590 (0.7%)
Alaahal Danandanay	123841 (24 0)	104676 (24 5%)	19165 (21.6%)

105 negative patients were similar in terms of other baseline characteristics, as well.

Drug Dependency	35969 (7.0%)	32203 (7.5%)	3766 (4.3%)
<b>Immunodeficien</b> cy	14572 (2.8%)	12442 (2.9%)	2130 (2.4%)
Mortality	88414 (17.1%)	72621 (16.4%)	15793 (16.9%)

106 **Table 1.** Baseline Characteristics.

- 107 Association of COVID-19 Infection and Decreased Cancer Risk
- 108 Having a positive COVID-19 infection was associated with a 25% decrease in the hazard of
- having a cancer diagnosis in the three years follow-up (HR=0.75, 95% CI: 0.74-0.77),
- 110 controlling for age, race, ethnicity, sex, BMI, smoking, kidney disease, COPD, diabetes,

111 hypertension, hyperlipidemia, obesity, chronic lung disease, PTSD, alcohol dependence, drug

dependence, being an active patient in the past 12 months, exposure to toxic substances, other

113 viral infections, and immunodeficiency.



	Number of events (%)	aHR (95% CI)
18-24 (n=3549)	17 (0.5%)	1.16 (0.37-3.63)
24-34 (n=44690)	383 (0.9%)	0.85 (0.65-1.12)
35-44 (n=61155)	1130 (1.8%)	0.93 (0.80-1.09)
45-54 (n=73400)	3334 (4.5%)	0.87 (0.79-0.95)
55-64 (n=112828)	11055 (9.8%)	0.84 (0.80-0.89)
65-74 (n=146407)	25956 (17.7%)	0.76 (0.73-0.79)
75-84 (n=53915)	11549 (21.4%)	0.74 (0.70-0.78)
85-99 (n=20201)	4155 (20.6%)	0.64 (0.58-0.70)

115 **Table 2.** aHR for New Cancer Diagnosis within three years for Patients with Positive COVID-19

116 Testing Compared to Patients of Negative Testing by Age

117

# 118 Association of COVID-19 Infection and Decreased Cancer Risk

- 119 by Age Groups, Gender, and Race.
- 120 We assessed the association between positive COVID-19 infection and the risk of having a
- 121 cancer diagnosis within three years in different age groups. We found that the older groups
- showed a greater reduction in the hazard of new cancer diagnosis. For the age group of 85-99,
- having a positive COVID-19 infection was associated with a 36% decrease in the hazard of
- having a cancer diagnosis in the three years follow-up (aHR: 0.64, 95% CI: 0.58-0.70), for age
- 125 group of 75-84, the reduction was 26% (aHR: 0.74, 95% CI: 0.70-0.78); and for the age group of
- 126 55-64, the reduction was 16% (aHR: 0.84, 95% CI:0.80-0.89) (Table 2). Regarding sex, the
- reduction in new cancer diagnosis was slightly higher in men (aHR: 0.74, 95% CI: 0.70-0.78)
- 128 than in women (aHR: 0.85, 95% CI: 0.76-0.94) (Table 3). Regarding race and ethnicity, the
- 129 reduction in new cancer diagnoses was similar between white, black, Asian, and Hispanic
- 130 populations (Table 4).

131

	aHR (95%CI)
Man	0.74 (0.73-0.76)
Women	0.85 (0.76-0.94)

132**Table 3.** aHR for New Cancer Diagnosis within three years for patients with positive COVID-19

133 testing compared to patients with negative testing by sex.

#### 135

	aHR (95% CI)
Black	0.79 (0.74-0.84)
White	0.74 (0.72-0.76)
Hispanic	0.76 (0.69-0.86)
Asian	0.76 (0.49-1.17)

136 **Table 4.** aHR for New Cancer Diagnosis within three years for Patients with Positive COVID-19

137 Testing Compared to Patients of Negative Testing by Race and Ethnicity.

## 138 Discussion

# 139 COVID-19 Exposure and Cancer Risk

140 Our findings show that beyond the age of 45, exposure to COVID-19 is associated with a 141 reduction in cancer incidence across all major cancer types. It is plausible that the immunologic 142 changes that occur during acute COVID-19 infection (10, 11) might lead to the activation of 143 monocytes with anticancer properties, as has been reported by other investigators (9), or another 144 process may lead to heightened immunity that has not been identified. The inflammatory 145 response to COVID-19 may have a short-term protective benefit that wanes over time. 146 Therefore, it is uncertain how long this risk reduction might be observed in the long-term beyond 147 the 3-year period of this study. Further research and longer follow-up periods are required to 148 fully understand the mechanisms responsible for the reduction in cancer incidence.

### 149 Pandemic Healthcare Disruptions

150 COVID-19 has introduced several new healthcare disruptions in cancer surveillance. 151 Cancer trends during the pandemic showed an initial reduction, followed by a general return to 152 the pre-pandemic levels (12, 13). These changes were expected, given the drastic reduction in 153 preventive services in the US (14). An analysis of trends in US cancer rates revealed the highest 154 variability in breast, cervical, prostate, and colorectal cancers, likely driven by a reduction in 155 surveillance screening (15). For this study, patients were analyzed for three years after the initial 156 index infection. This timeframe was extended to include the post-pandemic return to standard 157 screening; hence, the reduction we saw in our results is likely not a reflection of reduced 158 screening or missed diagnosis.

### 159 Age and Racial Differences

160 Racial and sex disparities are known to exist after COVID-19 infection, with men being 161 more likely to have adverse outcomes after infection (16). These racial and gender disparities 162 have improved over time (17) but remain an active area of investigation. Our findings showed 163 that the overall rate of cancer reduction was the same regardless of race or sex, except for 164 Asians, who comprised a small percentage of VA users. These findings were unexpected given 165 the known racial and ethnic disparities in cancer incidence (18). The relative uniformity of this 166 reduction across both sexes and races suggests the potential of a biological process independent 167 of these factors.

Regarding age, the incidence of cancer appeared to decrease with each decade of life in the COVID-19 group compared to that in the non-exposed group. This is surprising, given that cancer diagnoses typically increase with age. Several factors may contribute to this finding.

171 Older patients have a higher rate of death than younger patients with COVID-19 (19). Our study 172 examined patients during the initial alpha and delta waves. During the pandemic, mortality rates reached their highest point in the delta-wave cohort (20). We attempted to mitigate the risk of 173 174 survival bias by censoring and multivariate analyses for potential confounders. Our study 175 showed that mortality rates were similar between groups after the 30-day period. However, 176 several factors remain that cannot be adjusted through statistical processes. Given the reduction 177 in cancer rates across the board in the infected cohort, patients in this group who survived the 178 initial infection may have been at a lower risk for cancer due to environmental or genetic 179 reasons. Similarly, the increased mortality in this group could have conferred a survival 180 advantage regarding cancer risk. Therefore, care must be taken when attempting to link viral 181 exposure to reduced cancer outcomes, as these findings do not support causation.

### 182 Strengths and Limitations

183 Given the retrospective and observational nature of this study, the findings should be 184 interpreted with caution. One of the strengths of this study is that it comprises a large nationwide 185 database in which multiple risk factors and outcomes can be analyzed. An initial limitation of the 186 study is that this is only a 3-year cohort analysis of cancer incidence in a Veteran population that 187 is mostly comprised of male patients. These findings might change as five and ten-year data 188 become available and may be different in non-Veteran populations. Additionally, we attempted 189 to count for re-infection data; however, we were unable to capture all cases due to the increased 190 availability of COVID-19 testing outside of the VA (at-home testing, state, and county testing) 191 sites, among others) during subsequent re-infections and potentially milder disease or other 192 medical and socioeconomic reasons for which veterans did not seek medical attention. It is

193	unknown how reinfection alters the risk of cancer development in these patients, and the extent
194	to which it might induce other physiological changes.

# 195 Conclusion

- 196 Despite the limitations of our retrospective observational study, cancer incidence appears
- 197 to be lower in patients diagnosed with COVID-19 across all major cancers and independent of
- 198 race or sex. Further research is required to determine the precise causes and mechanisms
- 199 underlying these findings.

# 200 Acknowledgments

We would like to acknowledge the support of the Miami VAMC, Geriatric Research
Education and Clinical Center, and the US Veterans who served as our study population. This
study was supported using resources and facilities of VINCI, VA HSR RES 13-457
204
205
206
207
208
209
210
211

- 212
- 213
- 214
- 215
- 216
- References 217

218 Schiller JT, Lowy DR. An Introduction to Virus Infections and Human Cancer. Recent 1. 219 Results Cancer Res. 2021;217:1-11.

Kellogg C, Kouznetsova VL, Tsigelny IF. Implications of viral infection in cancer 220 2.

221 development. Biochim Biophys Acta Rev Cancer. 2021;1876(2):188622.

222 3. Morales-Sánchez A, Fuentes-Pananá EM. Human viruses and cancer. Viruses. 223 2014;6(10):4047-79.

224 Moore PS, Chang Y. Why do viruses cause cancer? Highlights of the first century of 4. 225 human tumour virology. Nat Rev Cancer. 2010;10(12):878-89.

226 Suryawanshi RK, Koganti R, Agelidis A, Patil CD, Shukla D. Dysregulation of Cell 5. 227 Signaling by SARS-CoV-2. Trends Microbiol. 2021;29(3):224-37.

Turnbull IR, Fuchs A, Remy KE, Kelly MP, Frazier EP, Ghosh S, et al. Dysregulation of 228 6. 229 the leukocyte signaling landscape during acute COVID-19. PLoS One. 2022;17(4):e0264979.

Gioia U, Tavella S, Martínez-Orellana P, Cicio G, Colliva A, Ceccon M, et al. SARS-230 7.

231 CoV-2 infection induces DNA damage, through CHK1 degradation and impaired 53BP1 232 recruitment, and cellular senescence. Nature Cell Biology. 2023;25(4):550-64.

233 Zhang D, Guo R, Lei L, Liu H, Wang Y, Wang Y, et al. Frontline Science: COVID-19 8. 234 infection induces readily detectable morphologic and inflammation-related phenotypic changes 235 in peripheral blood monocytes. J Leukoc Biol. 2021;109(1):13-22.

236 9. Liu X, Ren Z, Tan C, Núñez-Santana FL, Kelly ME, Yan Y, et al. Inducible CCR2+

237 nonclassical monocytes mediate the regression of cancer metastasis. J Clin Invest. 2024;134(22).

238 Manjili RH, Zarei M, Habibi M, Manjili MH. COVID-19 as an Acute Inflammatory 10. 239 Disease. J Immunol. 2020;205(1):12-9.

240 11. Wong RSY. Inflammation in COVID-19: from pathogenesis to treatment. Int J Clin Exp 241 Pathol. 2021;14(7):831-44.

242 Drescher CW, Bograd AJ, Chang SC, Weerasinghe RK, Vita A, Bell RB. Cancer case 12.

243 trends following the onset of the COVID-19 pandemic: A community-based observational study 244 with extended follow-up. Cancer. 2022;128(7):1475-82.

245 Decker KM, Feely A, Bucher O, Czaykowski P, Hebbard P, Kim JO, et al. New Cancer 13.

246 Diagnoses Before and During the COVID-19 Pandemic. JAMA Netw Open.

247 2023;6(9):e2332363.

248 14. Huggins A, Husaini M, Wang F, Waken RJ, Epstein AM, Orav EJ, et al. Care Disruption

249 During COVID-19: a National Survey of Hospital Leaders. Journal of general internal medicine.

250 2023;38(5):1232-8.

- 251 15. Shanmugam R, Fulton L, Kruse CS, Beauvais B, Betancourt J, Pacheco G, et al. The 252 effect of COVID-19 on cancer incidences in the U.S. Heliyon. 2024;10(7):e28804.
- 253 Pal S, Gangu K, Garg I, Shuja H, Bobba A, Chourasia P, et al. Gender and Race-Based 16.

254 Health Disparities in COVID-19 Outcomes among Hospitalized Patients in the United States: A 255 Retrospective Analysis of a National Sample. Vaccines (Basel). 2022;10(12).

- 256 Nguemeni Tiako MJ, Browne A. How race, sex and age interact in association with 17.
- 257 COVID-19 outcomes over time: An analysis of Michigan data. PLoS One. 2023;18(8):e0288383.
- 258 Zavala VA, Bracci PM, Carethers JM, Carvajal-Carmona L, Coggins NB, Cruz-Correa 18.
- 259 MR, et al. Cancer health disparities in racial/ethnic minorities in the United States. Br J Cancer. 260 2021;124(2):315-32.
- 261 19. Bonanad C, García-Blas S, Tarazona-Santabalbina F, Sanchis J, Bertomeu-González V,
- Fácila L, et al. The Effect of Age on Mortality in Patients With COVID-19: A Meta-Analysis 262
- With 611,583 Subjects. J Am Med Dir Assoc. 2020;21(7):915-8. 263
- 264 Lundberg DJ, Wrigley-Field E, Cho A, Raquib R, Nsoesie EO, Paglino E, et al. COVID-20.
- 19 Mortality by Race and Ethnicity in US Metropolitan and Nonmetropolitan Areas, March 2020 265
- 266 to February 2022. JAMA Netw Open. 2023;6(5):e2311098.